We are live on ! Find out more
PMVP icon

PMV Pharmaceuticals
PMVP

120 hedge funds and large institutions have $614M invested in PMV Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 43 increasing their positions, 32 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 10

52% more call options, than puts

Call options by funds: $558K | Put options by funds: $366K

34% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 32

14% more funds holding

Funds holding: 105 → 120 (+15)

6.61% less ownership

Funds ownership: 134.13% → 127.52% (-6.6%)

21% less capital invested

Capital invested by funds: $775M → $614M (-$161M)

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
120
Holders Change
+15
Holders Change %
+14.29%
% of All Funds
2.07%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.07%
New
25
Increased
43
Reduced
32
Closed
10
Calls
$558K
Puts
$366K
Net Calls
+$192K
Net Calls Change
-$4.91M

Top Buyers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
+$6.2M
2
BBA
Baker Bros. Advisors
New York
+$4.65M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$3.28M
4
MPAM
Monarch Partners Asset Management
Massachusetts
+$3.04M
5
Millennium Management
Millennium Management
New York
+$2.32M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$25.6M
2
State Street
State Street
Massachusetts
-$18.4M
3
Citadel Advisors
Citadel Advisors
Florida
-$6.37M
4
PHS
PFM Health Sciences
California
-$5.19M
5
BC
Boxer Capital
California
-$4.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
Assenagon Asset Management
26
Assenagon Asset Management
Luxembourg
$5.51M -$2.4M -166,193 -26%
Dimensional Fund Advisors
27
Dimensional Fund Advisors
Texas
$4.34M +$3.28M +227,157 +166%
BBA
28
Baker Bros. Advisors
New York
$3.83M +$4.65M +322,024 New
Northern Trust
29
Northern Trust
Illinois
$3.77M +$48.8K +3,381 +1%
Rafferty Asset Management
30
Rafferty Asset Management
New York
$3.44M +$714K +49,454 +21%
Citigroup
31
Citigroup
New York
$3.13M -$3.73M -258,145 -50%
Federated Hermes
32
Federated Hermes
Pennsylvania
$2.98M -$1.36K -94 -0%
Charles Schwab
33
Charles Schwab
California
$2.96M +$514K +35,579 +17%
Voloridge Investment Management
34
Voloridge Investment Management
Florida
$2.79M +$2.27M +157,440 +206%
MPAM
35
Monarch Partners Asset Management
Massachusetts
$2.5M +$3.04M +210,370 New
Barclays
36
Barclays
United Kingdom
$2.31M +$1.03M +71,120 +58%
SFM
37
Sphera Funds Management
Israel
$2.23M – – –
UBS AM
38
UBS AM
Illinois
$2.12M -$74.5K -5,157 -3%
CSS
39
Cubist Systematic Strategies
Connecticut
$2.12M +$1.9M +131,254 +280%
Millennium Management
40
Millennium Management
New York
$1.91M +$2.32M +160,496 New
ACP
41
Acuta Capital Partners
California
$1.84M +$28.9K +2,000 +1%
Verition Fund Management
42
Verition Fund Management
Connecticut
$1.72M +$1.37M +94,678 +191%
EW
43
Evoke Wealth
California
$1.58M – – –
Bank of New York Mellon
44
Bank of New York Mellon
New York
$1.46M +$257K +17,776 +17%
UBS Group
45
UBS Group
Switzerland
$1.43M -$3.33M -230,465 -66%
N
46
Nuveen
North Carolina
$1.39M -$8.49K -588 -0.5%
Susquehanna International Group
47
Susquehanna International Group
Pennsylvania
$1.23M +$1.02M +70,621 +215%
Tudor Investment Corp
48
Tudor Investment Corp
Connecticut
$1.02M +$1.24M +85,553 New
Ameriprise
49
Ameriprise
Minnesota
$956K -$22K -1,521 -2%
HF
50
HRT Financial
New York
$785K +$953K +65,996 New
1
2
3 4 5

PMVP Hedge Fund Activity: Q3 2022 in Review

120 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q3 2022, worth a combined $614M — down 21% from $775M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new PMVP positions and 10 closed out — a net gain of 15 holders — while 43 added to existing stakes and 32 trimmed.

The largest buyer was Woodline Partners, adding an estimated $6.2M. The largest seller was Morgan Stanley, cutting an estimated $25.6M.

  • 120 institutional investors held PMV Pharmaceuticals (PMVP) as of Q3 2022, up from 105 in Q2 2022.
  • Funds reported $614M of PMV Pharmaceuticals stock for Q3 2022, down 21% quarter-over-quarter.
  • 25 funds opened new PMV Pharmaceuticals positions in Q3 2022 and 10 closed out, a net change of +15 holders.
  • The largest PMV Pharmaceuticals buyer in Q3 2022 was Woodline Partners, an estimated $6.2M added.
  • The largest PMV Pharmaceuticals seller in Q3 2022 was Morgan Stanley, an estimated $25.6M sold.

Based on aggregated 13F filings for Q3 2022.